Adjunctive glucocorticoid therapy in patients with septic shock.
Open accessThe DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Whether hydrocortisone reduces mortality among patients with septic shock is unclear. METHODS: We randomly assigned patients with septic shock who were undergoing mechanical ventilation to receive hydrocortisone (at a dose of 200 mg per day) or placebo for 7 days or until death or discharge from the intensive care unit (ICU), whichever came first. The primary outcome was death from any cause at 90 days. RESULTS: From March 2013 through April 2017, a total of 3800 patients underwent randomization. Status with respect to the primary outcome was ascertained in 3658 patients (1832 of whom had been assigned to the hydrocortisone group and 1826 to the placebo group). At 90 days, 511 patients (27.9%) in the hydrocortisone group and 526 (28.8%) in the placebo group had died (odds ratio, 0.95; 95% confidence interval [CI], 0.82 to 1.10; P=0.50). The effect of the trial regimen was similar in six prespecified subgroups. Patients who had been assigned to receive hydrocortisone had faster resolution of shock than those assigned to the placebo group (median duration, 3 days [interquartile range, 2 to 5] vs. 4 days [interquartile range, 2 to 9]; hazard ratio, 1.32; 95% CI, 1.23 to 1.41; P<0.001). Patients in the hydrocortisone group had a shorter duration of the initial episode of mechanical ventilation than those in the placebo group (median, 6 days [interquartile range, 3 to 18] vs. 7 days [interquartile range, 3 to 24]; hazard ratio, 1.13; 95% CI, 1.05 to 1.22; P<0.001), but taking into account episodes of recurrence of ventilation, there were no significant differences in the number of days alive and free from mechanical ventilation. Fewer patients in the hydrocortisone group than in the placebo group received a blood transfusion (37.0% vs. 41.7%; odds ratio, 0.82; 95% CI, 0.72 to 0.94; P=0.004). There were no significant between-group differences with respect to mortality at 28 days, the rate of recurrence of shock, the number of days alive and out of the ICU, the number of days alive and out of the hospital, the recurrence of mechanical ventilation, the rate of renal-replacement therapy, and the incidence of new-onset bacteremia or fungemia. CONCLUSIONS: Among patients with septic shock undergoing mechanical ventilation, a continuous infusion of hydrocortisone did not result in lower 90-day mortality than placebo. (Funded by the National Health and Medical Research Council of Australia and others; ADRENAL ClinicalTrials.gov number, NCT01448109 .).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Since then, three large RCTs have been published [354, 478, 479].”
From Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021 (2021) · cites this paper as [479]
In the citing paper
“The optimal dose, timing of initiation, and duration of corticosteroids remain uncertain; recent RCTs used 200 mg per day of IV hydrocortisone in divided doses [354, 479].”
From Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021 (2021) · cites this paper as [479]
In the citing paper
“The three trials [354, 478, 479] also used different inclusion criteria: in ADRENAL [479] eligible patients were those on any dose of vasopressor or inotrope for ≥ 4 h to maintain a MAP > 60 mmHg, and present at the time of randomisation.”
From Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021 (2021) · cites this paper as [479]
In the citing paper
“In the ADRENAL [479] study, hydrocortisone was administered for a maximum of seven days or until ICU discharge or death; in APROCCHSS [478] hydrocortisone was administered for seven days; in VANISH [354] 200 mg of hydrocortisone was administered daily for 5 days and then tapered over further 6 days.”
From Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021 (2021) · cites this paper as [479]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The third international consensus definitions for sepsis and septic shock (Sepsis-3).
Singer, M., Deutschman, C. S., Seymour, C. W., Shankar-Hari, M., Annane, D., Bauer, M., Bellomo, R., Bernard, G. R., Chiche, J.-D., Coopersmith, C. M., et al. (2016) · JAMA · doi:10.1001/jama.2016.0287 · Cited by 28,250
Self-citationA Simple Sequentially Rejective Multiple Test Procedure
(1979) · Scandinavian Journal of Statistics · doi:10.2307/4615733 · Cited by 21,526
APACHE II: A severity of disease classification system
KNAUS, W. A., DRAPER, E. A., WAGNER, D. P., & ZIMMERMAN, J. E. (1985) · Critical Care Medicine · doi:10.1097/00003246-198510000-00009 · Cited by 13,664
Bone, R. C., Balk, R. A., Cerra, F. B., Dellinger, R. P., Fein, A. M., Knaus, W. A., Schein, R. M. H., & Sibbald, W. J. (1992) · Chest · doi:10.1378/chest.101.6.1644 · Cited by 13,198
Surviving Sepsis Campaign: International guidelines for management of sepsis and septic shock: 2016.
Rhodes, A., Evans, L. E., Alhazzani, W., Levy, M. M., Antonelli, M., Ferrer, R., Kumar, A., Sevransky, J. E., Sprung, C. L., Nunnally, M. E., et al. (2017) · Intensive Care Medicine · doi:10.1007/s00134-017-4683-6 · Cited by 6,621
Self-citationFleischmann, C., Scherag, A., Adhikari, N. K. J., Hartog, C. S., Tsaganos, T., Schlattmann, P., Angus, D. C., & Reinhart, K. (2016) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201504-0781oc · Cited by 3,548
Annane, D. (2002) · JAMA · doi:10.1001/jama.288.7.862 · Cited by 3,087
The Hypothalamic–Pituitary–Adrenal Axis and Immune-Mediated Inflammation
Chrousos, G. P. (1995) · New England Journal of Medicine · doi:10.1056/nejm199505183322008 · Cited by 2,579
Hydrocortisone Therapy for Patients with Septic Shock
Sprung, C. L., Annane, D., Keh, D., Moreno, R., Singer, M., Freivogel, K., Weiss, Y. G., Benbenishty, J., Kalenka, A., Forst, H., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa071366 · Cited by 2,132
Incidence and trends of sepsis in US hospitals using clinical vs claims data, 2009-2014.
Rhee, C., Dantes, R., Epstein, L., Murphy, D. J., Seymour, C. W., Iwashyna, T. J., Kadri, S. S., Angus, D. C., Danner, R. L., Fiore, A. E., et al. (2017) · JAMA · doi:10.1001/jama.2017.13836 · Cited by 1,884
Cited by
Items 201–300 of 1,000
Infection, Sepsis and the Inflammatory Response: Mechanisms and Therapy
Lonsdale, D., Shah, R. V., & Lipman, J. (2020) · Frontiers in Medicine · doi:10.3389/fmed.2020.588863 · Cited by 35
“Some also advocate corticosteroid use (200 mg/day for 7-days) in septic shock refractory to fluid and vasopressor therapy, citing shorter time to resolution of shock and shorter ICU stay (62, 63).”
BackgroundMedication and Fluid Management of Pediatric Sepsis and Septic Shock
Burgunder, L., Heyrend, C., Olson, J. A., Stidham, C., Lane, R. D., Workman, J. K., & Larsen, G. Y. (2022) · Pediatric Drugs · doi:10.1007/s40272-022-00497-z · Cited by 36
“4 days), but—as demonstrated in previous studies— was more likely to have hyperglycemia, hypernatremia, and myopathy [119].”
BackgroundHuang, H., Wu, C., Shen, Q., Xu, H., Fang, Y., & Mao, W. (2021) · The American Journal of Emergency Medicine · doi:10.1016/j.ajem.2021.05.007 · Cited by 39
What is new and different in the 2021 Surviving Sepsis Campaign guidelines
Prescott, H. C., & Ostermann, M. (2023) · Medizinische Klinik - Intensivmedizin und Notfallmedizin · doi:10.1007/s00063-023-01028-5 · Cited by 45
Pulmonary Delivery of Fenretinide: A Possible Adjuvant Treatment in COVID-19
Orienti, I., Gentilomi, G. A., & Farruggia, G. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21113812 · Cited by 34
Predictors of dysrhythmias with norepinephrine use in septic shock
Wieruszewski, E. D., Jones, G. M., Samarin, M. J., & Kimmons, L. A. (2020) · Journal of Critical Care · doi:10.1016/j.jcrc.2020.10.023 · Cited by 34
Sepsis in the critically ill patient: current and emerging management strategies
Heming, N., Azabou, É., Cazaumayou, X., Moine, P., & Annane, D. (2020) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2021.1846522 · Cited by 36
“received either a continuous intravenous administration of 200 mg of hydrocortisone a day over 7 days or placebo [56].”
MethodLi, J., Liu, L., Zhou, X., Lu, X., Liu, X., Li, G., & Long, J. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.590652 · Cited by 33
“Frontiers in Pharmacology | www.frontiersin.org December 2020 | Volume 11 | Article 5906528 withdrawal of corticosteroids (Peter et al., 2008; Annane et al., 2018; Duran et al., 2018; Venkatesh et al., 2018; Yao et al., 2020).”
BackgroundGuinot, P., Martin, A., Berthoud, V., Voizeux, P., Bartamian, L., Santangelo, E., Bouhemad, B., & Nguyen, M. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10143164 · Cited by 38
Li, J. X. L., Wang, X., Henry, A., Anderson, C. S., Hammond, N. E., Harris, K., Liu, H., Loffler, K. A., Myburgh, J., Pandian, J. D., et al. (2023) · Pain · doi:10.1097/j.pain.0000000000002884 · Cited by 33
Self-citationThe “cytokine storm” in infection and sepsis: win the battle but lose the war
Fan, J., Li, Q.-Y., Feng, X.-F., Huang, S., Wang, R., Liao, F.-Y., Liu, D., Liu, W.-Y., Sun, J.-H., Zhang, H.-C., et al. (2026) · Military Medical Research · doi:10.1186/s40779-025-00678-0 · Cited by 52
“For example, in patients with septic shock requiring vasoactive drugs, the initiation of low-dose hydrocortisone (200 mg/d) within 24 h of diagnosis is recommended [189, 190].”
Self-citationMehta, H. B., An, H., Andersen, K. M., Mansour, O., Madhira, V., Rashidi, E., Bates, B. A., Setoguchi, S., Joseph, C., Kocis, P. T., et al. (2021) · Annals of Internal Medicine · doi:10.7326/m21-0857 · Cited by 32
Insights Into Thiamine Supplementation in Patients With Septic Shock
Costa, N. A., Pereira, A. G., Sugizaki, C. S. D. A., Vieira, N. M., Garcia, L. R., de Paiva, S. A. R., Zornoff, L. A. M., Azevedo, P. S., Polegato, B. F., & Minicucci, M. F. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2021.805199 · Cited by 32
“It is important to note that hydrocortisone monotherapy in patients with septic shock is associated with faster resolution of shock (70) and lower mortality (71) when compared with placebo groups.”
BackgroundSepsis and Adrenal Insufficiency
Fowler, C., Raoof, N. D., & Pastores, S. M. (2023) · Journal of Intensive Care Medicine · doi:10.1177/08850666231183396 · Cited by 34
“In fact, the largest study (ADRENAL) 47 also noted a shorter time to ICU discharge.”
BackgroundInfluentialSepsis subphenotypes: bridging the gaps in sepsis treatment strategies
Zhang, X., Zhang, W., Zhang, H., & Liao, X. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1546474 · Cited by 39
Emerging therapeutic targets for sepsis
Tindal, E. W., Armstead, B. E., Monaghan, S. F., Heffernan, D. S., & Ayala, A. (2021) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2021.1897107 · Cited by 33
Roles of ginsenosides in sepsis
Yu, T., Tang, Y., Zhang, F., & Zhang, L. (2022) · Journal of Ginseng Research · doi:10.1016/j.jgr.2022.05.004 · Cited by 32
“In 2018, two clinical trials, both published in the New England Journal of Medicine, reported contrary findings on the efficacy of GCs in reducing sepsis-related death [36,37].”
Backgroundvon Groote, T., & Meersch, M. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11195782 · Cited by 35
Yu, T., Cheng, H., Li, X., Huang, W., Li, H., Gao, X., Zhao, J., Zhang, X., Gu, X., Bi, Y., et al. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114911 · Cited by 31
Hemodynamic management of septic shock: beyond the Surviving Sepsis Campaign guidelines
Suh, G. J., Shin, T. G., Kwon, W. Y., Kim, K., Jo, Y. H., Choi, S., Chung, S. P., Kim, W. Y., & for the Korean Shock Society investigators (2023) · Clinical and Experimental Emergency Medicine · doi:10.15441/ceem.23.065 · Cited by 32
“Three recent large RCTs [60–62] showed that corticosteroids accelerate the resolution of shock, but there was no clear effect on short-or long-term mortality.”
BackgroundPetersen, M. W., Meyhoff, T. S., Helleberg, M., Kjær, M. N., Granholm, A., Hjortsø, C. J. S., Jensen, T. S., Møller, M. H., Hjortrup, P. B., Wetterslev, M., et al. (2020) · Acta Anaesthesiologica Scandinavica · doi:10.1111/aas.13673 · Cited by 30
Self-citationLi, Y., Xu, Y., Li, W., Li, J., Wu, W., Kang, J., Jiang, H., Liu, P., Liu, J., Gong, W., et al. (2023) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-023-04971-w · Cited by 32
“As a widely known anti-inflammatory drug, glucocorticoids are only approved for use in patients diagnosed with sepsis shock due to their side effects [52].”
BackgroundChaudhuri, D., Israelian, L., Putowski, Z., Prakash, J., Pitre, T., Nei, A. M., Spencer-Segal, J. L., Gershengorn, H. B., Annane, D., Pastores, S. M., et al. (2024) · Critical Care Explorations · doi:10.1097/cce.0000000000001071 · Cited by 40
Emergency medicine updates: Management of sepsis and septic shock
Long, B., & Gottlieb, M. A. (2025) · The American Journal of Emergency Medicine · doi:10.1016/j.ajem.2025.01.054 · Cited by 34
Catecholamine Vasopressor Support Sparing Strategies in Vasodilatory Shock
Buckley, M. S., Barletta, J. F., Smithburger, P. L., Radosevich, J. J., & Kane‐Gill, S. L. (2018) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.2199 · Cited by 30
“In contrast, one study did not show a benefit with corticosteroid administration.(55) Inclusion criteria for this study required any vasopressor use for a minimum of 4 hours, and total mortality rate was 28.”
BackgroundRagoonanan, D., Allen, B., Cannon, C., Rottman-Pietrzak, K., & Bello, A. (2021) · Annals of Pharmacotherapy · doi:10.1177/10600280211021103 · Cited by 30
“0099 NE-equivalent dose at HC initiation (μg/min) 20 (9-30) 12 (5-24) 0.”
Fong, K. M., Au, S. Y., & Ng, G. W. Y. (2021) · Scientific Reports · doi:10.1038/s41598-021-95386-9 · Cited by 30
Long-term prognosis of septic shock in cancer patients
Camou, F., Didier, M., Leguay, T., Milpied, N. J., Daste, A., Ravaud, A., Mourissoux, G., Guisset, O., & Issa, N. (2019) · Supportive Care in Cancer · doi:10.1007/s00520-019-04937-4 · Cited by 34
Management of Vasoplegic Shock in the Cardiovascular Intensive Care Unit after Cardiac Surgery
Suero, O. R., Park, Y., Wieruszewski, P. M., & Chatterjee, S. (2023) · Critical Care Clinics · doi:10.1016/j.ccc.2023.06.002 · Cited by 29
Current perspectives in the management of sepsis and septic shock
Chiscano‐Camón, L., Ruiz‐Sanmartín, A., Bajaña, I., Bastidas, J., López‐Martínez, R., Franco‐Jarava, C., González‐López, J. J., Larrosa, N., Riera, J., Nuvials, X., et al. (2024) · Frontiers in Medicine · doi:10.3389/fmed.2024.1431791 · Cited by 36
Neutrophil Hitchhiking Enhances Liposomal Dexamethasone Therapy of Sepsis
Mathur, R., Elsafy, S., Press, A. T., Brück, J., Hornef, M. W., Märtin, L., Schürholz, T., Marx, G., Bartneck, M., Kiessling, F. M., et al. (2024) · ACS Nano · doi:10.1021/acsnano.4c09054 · Cited by 33
Rajendran, S., Xu, Z., Pan, W., Zang, C., Siempos, I. Ι., Torres, L. K., Xu, J., Bian, J., Schenck, E. J., & Wang, F. (2025) · Nature Communications · doi:10.1038/s41467-025-59643-z · Cited by 29
“This is a limitation of real-world data, as in RCTs, steroids and cohort determination would occur simultaneously.”
InfluentialLong-Term Outcomes of the ADRENAL Trial
Venkatesh, B., Finfer, S. R., Myburgh, J., Cohen, J., & Billot, L. (2018) · New England Journal of Medicine · doi:10.1056/nejmc1803563 · Cited by 28
Self-citationThe Future of Critical Care Lies in Quality Improvement and Education
Niven, A. S., Herasevich, S., Pickering, B. W., & Gajic, O. (2019) · Annals of the American Thoracic Society · doi:10.1513/annalsats.201812-847ip · Cited by 29
Kim, W., Jung, J., Choi, J. C., Shin, J. W., & Kim, J. Y. (2019) · Nutrients · doi:10.3390/nu11122976 · Cited by 29
“Nevertheless, most sepsis trials have focused on a one-size-fits-all approach, which may partially explain the inconsistent results from the aforementioned studies [9,10].”
BackgroundMethodResultInfluentialHosseinzadeh, M. H., Shamshirian, A., & Ebrahimzadeh, M. A. (2020) · International Journal of Clinical Practice · doi:10.1111/ijcp.13943 · Cited by 29
Shankar‐Hari, M., Santhakumaran, S., Prevost, A. T., Ward, J. K., Marshall, T. J., Bradley, C., Calfee, C. S., Delucchi, K., Sinha, P., Matthay, M. A., et al. (2021) · Efficacy and Mechanism Evaluation · doi:10.3310/eme08100 · Cited by 31
Téblick, A., Dyck, L. V., Aerde, N. V., Perre, S. V., Pauwels, L., Derese, I., Debaveye, Y. A., Wouters, P. J., Vanhorebeek, I., Langouche, L., et al. (2022) · EBioMedicine · doi:10.1016/j.ebiom.2022.104057 · Cited by 31
Decreased glucocorticoid receptor expression during critical illness
Vassiliou, A. G., Floros, G., Jahaj, E., Stamogiannos, G., Gennimata, S., Vassiliadi, D. A., Tsagarakis, S., Tzanela, M., Ilias, Ι., Orfanos, S. E., et al. (2019) · European Journal of Clinical Investigation · doi:10.1111/eci.13073 · Cited by 28
“It is of interest that two large studies have demonstrated no significant difference in mortality between patients with septic shock receiving low‐ dose hydrocortisone compared to placebo (Corticus and Adrenal studies).(7,8) The actions of glucocorticoids are mediated by a ubiquitous intracellular receptor protein, th…”
BackgroundMetabolic support in sepsis: corticosteroids and vitamins: the why, the when, the how
Fujii, T., Deane, A. M., & Nair, P. (2020) · Current Opinion in Critical Care · doi:10.1097/mcc.0000000000000736 · Cited by 30
Role of the inflammatory response in community-acquired pneumonia: clinical implications
Rombauts, A., Abelenda-Alonso, G., Cuervo, G., Gudiol, C., & Carratalà, J. (2020) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2021.1834848 · Cited by 31
Lian, X., Huang, D., Cao, Y., Wei, Y.-X., Lian, Z., Qin, T., He, P.-C., Liu, Y.-H., & Wang, S. (2019) · BioMed Research International · doi:10.1155/2019/3175047 · Cited by 29
“In addition, during data extraction, sample size of different studies showed huge fluctuations ranged from 24 (Mussack 2005 [32]) to 3658 (Venkatesh 2018 [15]) and different survival benefits on subgroup analysis.”
Lu, X., Wang, X., Gao, Y., Yu, S., Zhao, L., Zhang, Z., Zhu, H., & Li, Y. (2020) · The American Journal of Emergency Medicine · doi:10.1016/j.ajem.2020.02.002 · Cited by 33
Evaluation of the Initiation Timing of Hydrocortisone in Adult Patients With Septic Shock
Sacha, G. L., Chen, A. Y., Palm, N. M., & Duggal, A. (2020) · Shock · doi:10.1097/shk.0000000000001651 · Cited by 27
“01) compared with those who received placebo (9).”
BackgroundMethodResultInfluentialCohen, J., Blumenthal, A., Cuéllar-Partida, G., Evans, D. M., Finfer, S. R., Li, Q., Ljungberg, J. K., Myburgh, J., Peach, E., Powell, J. E., et al. (2021) · Intensive Care Medicine · doi:10.1007/s00134-021-06464-5 · Cited by 28
Self-citationSepsis Management for the Nephrologist
Patel, S., Puri, N., & Dellinger, R. P. (2022) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.14381121 · Cited by 30
Bologheanu, R., Kapral, L., Laxar, D., Maleczek, M., Dibiasi, C., Zeiner, S., Agibetov, A., Ercole, A., Thoral, P., Elbers, P., et al. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12041513 · Cited by 34
Fleuriet, J., Heming, N., Meziani, F., Reignier, J., Declercq, P.-L., Mercier, E., Müller, G., Colin, G., Monnet, X., Robine, A., et al. (2023) · BMJ Open · doi:10.1136/bmjopen-2022-066496 · Cited by 28
Young, A., & Marsh, S. (2018) · BJA Education · doi:10.1016/j.bjae.2018.01.005 · Cited by 29
Sex differences in response to adjunctive corticosteroid treatment for patients with septic shock
Thompson, K., Venkatesh, B., Hammond, N. E., Taylor, C. B., Finfer, S. R., Bompoint, S., Carcel, C., Cohen, J., Jan, S., Myburgh, J., et al. (2021) · Intensive Care Medicine · doi:10.1007/s00134-020-06325-7 · Cited by 31
Self-citationSiew, L. Y., Lee, Z., Yunos, N. M., Atan, R., Cove, M. E., Lumlertgul, N., Srisawat, N., & Hasan, M. S. (2024) · Journal of Critical Care · doi:10.1016/j.jcrc.2024.154844 · Cited by 29
Aiming for precision: personalized medicine through sepsis subtyping
Kolodyazhna, A., Wiersinga, W. J., & van der Poll, T. (2025) · Burns & Trauma · doi:10.1093/burnst/tkae073 · Cited by 34
A Bayesian analysis of mortality outcomes in multicentre clinical trials in critical care
Sidebotham, D. A., Popovich, I., & Lumley, T. (2021) · British Journal of Anaesthesia · doi:10.1016/j.bja.2021.06.026 · Cited by 28
The Search for Efficacious New Therapies in Sepsis Needs to Embrace Heterogeneity
Scicluna, B. P., & Baillie, J. K. (2018) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201811-2148ed · Cited by 28
Steroids for sepsis and ARDS: this eternal controversy remains with COVID-19
Carlet, J. M., Payen, D. M., & Opal, S. M. (2020) · The Lancet · doi:10.1016/s0140-6736(20)32132-2 · Cited by 28
Nunnally, M., & Patel, A. (2019) · Current Opinion in Anaesthesiology · doi:10.1097/aco.0000000000000707 · Cited by 27
Management of Endocrine Emergencies in the ICU
Jacobi, J. (2019) · Journal of Pharmacy Practice · doi:10.1177/0897190019834771 · Cited by 26
Macrophages-regulating nanomedicines for sepsis therapy
Deng, J., Wang, R., Huang, S., Ding, J., & Zhou, W. (2022) · Chinese Chemical Letters · doi:10.1016/j.cclet.2022.06.011 · Cited by 25
How We Escalate Vasopressor and Corticosteroid Therapy in Patients With Septic Shock
Teja, B. J., Bosch, N. A., & Walkey, A. J. (2022) · CHEST Journal · doi:10.1016/j.chest.2022.09.019 · Cited by 33
Cytokine Release Syndrome and Sepsis
Athale, J., Busch, L. M., & O’Grady, N. P. (2022) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2022.07.001 · Cited by 29
Schlapbach, L. J., Raman, S., Buckley, D. H. F., George, S., King, M., Ridolfi, R., Harley, A., Cree, M., Long, D. A., Erickson, S. J., et al. (2024) · Pediatric Critical Care Medicine · doi:10.1097/pcc.0000000000003346 · Cited by 25
Self-citationFludrocortisone dose–response relationship in septic shock: a randomised phase II trial
Walsham, J., Hammond, N. E., Blumenthal, A., Cohen, J., Myburgh, J., Finfer, S. R., Evans, D. M., Peake, S., Krüger, P., McCullough, J., et al. (2024) · Intensive Care Medicine · doi:10.1007/s00134-024-07616-z · Cited by 25
“Assuming a shock reversal rate of 80% based on the ADRENAL [2] dataset in the hydrocortisone group, if each dose of fludrocortisone provided another 3–5% incremental shock reversal rate, the planned 300 patient study would have 70–80% power to test the trend of shock reversal across the four groups.”
InfluentialSelf-citationWhy My Steroid Trials in Septic Shock Were “Positive”
Annane, D. (2019) · Critical Care Medicine · doi:10.1097/ccm.0000000000003889 · Cited by 28
Donaldson, L., Vlok, R. A., Sakurai, K., Burrows, M., McDonald, G., Venkatesh, K., Bagshaw, S. M., Bellomo, R., Delaney, A. P., Myburgh, J., et al. (2024) · Critical Care Medicine · doi:10.1097/ccm.0000000000006284 · Cited by 29
Self-citationCheng, L., Cao, Y., Liu, S., Lv, L., Zhang, J., Bao, J., Wang, G., & Xu, P. (2025) · International Journal of Surgery · doi:10.1097/js9.0000000000002668 · Cited by 35
“These two studies recruited a total of 5041 patients, and the ADRENAL trial (Corticosteroid Therapy for Septic Shock and Adrenal Insufficiency) showed that hydrocortisone treatment did not improve the 90-day survival rate [ 367 ] .”
Sepsis: Changing Definitions, Unchanging Treatment
Obonyo, N. G., Schlapbach, L. J., & Fraser, J. F. (2019) · Frontiers in Pediatrics · doi:10.3389/fped.2018.00425 · Cited by 26
Chaudhuri, D., Nei, A. M., Rochwerg, B. N., BALK, R. A., Asehnoune, K., Cadena, R. S., Carcillo, J. A., Correa, R. R., Drover, K., Esper, A. M., et al. (2024) · Critical Care Medicine · doi:10.1097/ccm.0000000000006171 · Cited by 27
Neuroimmune modulation by tryptophan derivatives in neurological and inflammatory disorders
Kondo, T., Okada, Y., Saika, S., Yamaguchi, N., Hatakeyama, S., & Maruyama, K. (2024) · European Journal of Cell Biology · doi:10.1016/j.ejcb.2024.151418 · Cited by 24
Song, L. C., Chen, X. X., Meng, J. G., Hu, M., Huan, J. B., Wu, J., Xiao, K., Han, Z. H., & Xie, L. (2019) · International Immunopharmacology · doi:10.1016/j.intimp.2019.03.051 · Cited by 25
Beyond Mean Arterial Pressure and Lactate: Perfusion End Points for Managing the Shocked Patient
Hallisey, S. D., & Greenwood, J. C. (2019) · Emergency Medicine Clinics of North America · doi:10.1016/j.emc.2019.03.005 · Cited by 27
Venkatesh, B., Finfer, S. R., Cohen, J., Rajbhandari, D., Arabi, Y. M., Bellomo, R., Billot, L., Glass, P., Joyce, C., Li, Q., et al. (2019) · Anesthesiology · doi:10.1097/aln.0000000000002955 · Cited by 25
Self-citationCorticosteroids for treating sepsis in children and adults
Annane, D., Briegel, J., Granton, D., Bellissant, É., Bollaert, P., Keh, D., Kupfer, Y. Y., Pirracchio, R., & Rochwerg, B. N. (2025) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002243.pub5 · Cited by 40
Fitzgerald, D. B., WATERER, G. W., Budgeon, C. A., Shrestha, R. L., Fysh, E. T. H., Muruganandan, S., Stanley, C., Saghaie, T., Badiei, A., Sidhu, C., et al. (2022) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202107-1600oc · Cited by 23
Evolving Paradigms in Sepsis Management: A Narrative Review
Kim, M., Choi, E.-J., & Choi, E.-J. (2024) · Cells · doi:10.3390/cells13141172 · Cited by 27
“Similarly, the ADRENAL trial observed that, despite hastening septic shock resolution and reducing the need for blood transfusions, hydrocortisone did not significantly improve the 28-or 90-day mortality rates [75].”
BackgroundHuman DNA methylation signatures differentiate persistent from resolving MRSA bacteremia
Chang, Y., Rossetti, M. M., Gjertson, D. W., Rubbi, L., Thompson, M. J., Montoya, D. J., Morselli, M., Ruffin, F., Hoffmann, A., Pellegrini, M. A., et al. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2000663118 · Cited by 24
Zhang, W., Qin, C., Fei, Y., Shen, M. Y., Zhou, Y., Zhang, Y., Zeng, X., & Zhang, S. (2022) · Clinical Immunology · doi:10.1016/j.clim.2022.109022 · Cited by 24
Multiple organ failure: What you need to know
Brakenridge, S. C., Kornblith, L. Z., & Cuschieri, J. (2024) · The Journal of Trauma: Injury, Infection, and Critical Care · doi:10.1097/ta.0000000000004419 · Cited by 22
Zhan, J., Wei, J., Liu, Y., Wang, P.-X., & Zhu, X. (2025) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2025.139548 · Cited by 29
Fujii, T., Udy, A. A., Deane, A. M., Luethi, N., Bailey, M., Eastwood, G. M., Frei, D. R., French, C., Orford, N. R., Shehabi, Y., et al. (2019) · Critical Care and Resuscitation · doi:10.1016/s1441-2772(23)00661-0 · Cited by 23
Self-citationvan Heerden, P. V., Abutbul, A., Sviri, S., Zlotnick, E., Nama, A., Zimro, S., el-Amore, R., Shabat, Y., Reicher, B., Falah, B., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.718191 · Cited by 26
Dessap, A. M., Bagate, F., Delmas, C., Morichau-Beauchant, T., Cholley, B., Cariou, A., Lattuca, B., Moussa, M. D., Mongardon, N., Fard, D., et al. (2022) · Trials · doi:10.1186/s13063-021-05947-6 · Cited by 24
“These results were recently confirmed by APROCCHSS and ADRENAL trials [11, 12].”
BackgroundResultNociceptor-derived Reg3γ prevents endotoxic death by targeting kynurenine pathway in microglia
Sugisawa, E., Kondo, T., Kumagai, Y., Kato, H., Takayama, Y., Isohashi, K., Shimosegawa, E., Takemura, N., Hayashi, Y., Sasaki, T., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.110462 · Cited by 23
Lai, P.-C., Lai, C., Lai, E. C., & Huang, Y. (2023) · Critical Care Medicine · doi:10.1097/ccm.0000000000006161 · Cited by 29
Allen, J. M., Feild, C. J., Shoulders, B. R., & Voils, S. A. (2018) · Annals of Pharmacotherapy · doi:10.1177/1060028018812940 · Cited by 23
Cost-effectiveness of second-line vasopressors for the treatment of septic shock
Lam, S. W., Barreto, E. F., Scott, R. A., KASHANI, K. B., Khanna, A. K., & Bauer, S. R. (2019) · Journal of Critical Care · doi:10.1016/j.jcrc.2019.10.005 · Cited by 23
Sun, B., Luan, C., Guo, L., Zhang, B., & Liu, Y. (2020) · Brazilian Journal of Medical and Biological Research · doi:10.1590/1414-431x20209501 · Cited by 22
“About 50% of sepsis patients require intensive care unit treatment (2,3), leading to high morbidity and mortality (4,5).”
BackgroundJamshidi, M. R., Zeraati, M. R., Forouzanfar, B., Tahrekhani, M., & Motamed, N. (2021) · Journal of Research in Medical Sciences · doi:10.4103/jrms.jrms_593_19 · Cited by 28
“[29] However, the ADRENAL study which enrolled septic shock patients with a lower severity of illness failed to replicate these findings, suggesting that only the sickest patients benefit from corticosteroids.[30] Zabet et al.”
A Role for Hydrocortisone Therapy in Septic Shock?
Suffredini, A. F. (2018) · New England Journal of Medicine · doi:10.1056/nejme1801463 · Cited by 23
Sepsis: the evolution of molecular pathogenesis concepts and clinical management
Feng, Z., Wang, L., Yang, J. L., Li, T., Liao, X., Kang, Y. M., Xiao, F., & Zhang, W. (2025) · MedComm · doi:10.1002/mco2.70109 · Cited by 26
Jozwiak, M., Cousin, V. L., Backer, D. D., Malbrain, M. L. N. G., Monnet, X., Messina, A., Chew, M. S., & the Cardiovascular Dynamics section of the European Society of Intensive Care Medicine (2025) · Critical Care · doi:10.1186/s13054-025-05505-5 · Cited by 24
“Only 66% of respondents administered corticosteroids before considering a second-line vasopressor, even though it has been shown that corticosteroids administration can also reduce the vasopressor load and hasten the resolution of shock [23, 24].”
He, H., Liu, D., Long, Y., Wang, X., & Yao, B. (2018) · Inflammation · doi:10.1007/s10753-018-0846-z · Cited by 23
Does asymmetry in patient recruitment in large critical care trials follow the Pareto principle?
Ramanan, M., Billot, L., Rajbhandari, D., Myburgh, J., Finfer, S. R., Bellomo, R., & Venkatesh, B. (2020) · Trials · doi:10.1186/s13063-020-04279-1 · Cited by 24
Self-citationYelle, S., & Rajyalakshmi, B. (2020) · Indian Journal of Critical Care Medicine · doi:10.5005/jp-journals-10071-23515 · Cited by 23
Wu, T., Hu, C., Huang, W., Xu, Q., Hu, B., & Li, J. (2021) · Shock · doi:10.1097/shk.0000000000001781 · Cited by 22
“Didier and colleagues indicated that adjunctive hydrocortisone therapy did not prevent the evolution from severe sepsis to septic shock (31), but others in contrast reported a significant reduction in the time to resolution of shock (32, 33).”
BackgroundThe story of critical care in Asia: a narrative review
Phua, J., Lim, C., Faruq, M. O., Nafees, K. M. K., Du, B., Gomersall, C. D., Ling, L., Divatia, J. V., Hashemian, S. M. R., Egi, M., et al. (2021) · Journal of Intensive Care · doi:10.1186/s40560-021-00574-4 · Cited by 26
Self-citationNovel insights in endocrine and metabolic pathways in sepsis and gaps for future research
Téblick, A., Gunst, J., Langouche, L., & den Berghe, G. V. (2022) · Clinical Science · doi:10.1042/cs20211003 · Cited by 24
Retinoic Acid-Induced Regulation of Inflammatory Pathways Is a Potential Sepsis Treatment
Dolin, H. H., Franco, J. H., Chen, X., & Pan, Z. K. (2023) · Infection and Immunity · doi:10.1128/iai.00457-22 · Cited by 21
Steroids for sepsis: yes, no or maybe
Marik, P. E. (2018) · Journal of Thoracic Disease · doi:10.21037/jtd.2018.04.35 · Cited by 22
Major publications in critical care pharmacotherapy literature in 2018
Sikora, A. N., Bissell, B. D., Burry, L. D., Defayette, A. A., Gagnon, D. J., Gilbert, B. W., Kramer, C. J., Miller, C. J., Semanco, M., Smith, M. N., et al. (2019) · Journal of Critical Care · doi:10.1016/j.jcrc.2019.04.029 · Cited by 21
Zhang, S., Chang, W., Xie, J., Wu, Z., Yang, Y., & Qiu, H. (2020) · Critical Care Explorations · doi:10.1097/cce.0000000000000094 · Cited by 22
Metadata
- Authors
- Venkatesh, B., Finfer, S., Cohen, J., Rajbhandari, D., Arabi, Y., Bellomo, R., Billot, L., Correa, M., Glass, P., Harward, M., Joyce, C., Li, Q., McArthur, C., Perner, A., Rhodes, A., Thompson, K., Webb, S., & Myburgh, J.
- Affiliations
- The University of Sydney (AU)
- From the George Institute for Global Health, University of New South Wales (B.V., S.F., D.R., L.B., M.C., P.G., M.H., Q.L., K.T., J.M.), St. George Clinical School, St. George Hospital (J.M.), Sydney Medical School, University of Sydney (B.V., S.F., J.M.), and Royal North Shore Hospital (S.F.), Sydney, the Princess Alexandra Hospital (B.V., C.J.) and Royal Brisbane and Women’s Hospital (J.C.), University of Queensland, and the Wesley Hospital (B.V., J.C.), Brisbane, Austin Hospital (R.B.), the...
- University of Copenhagen (DK)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2018-03
- Volume
- 378
- Issue
- 9
- Pages
- 797-808
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2784412824
- Cited by
- 1,037
- References
- 40
- Citations by year
- 2026: 111 · 2025: 122 · 2024: 90 · 2023: 106 · 2022: 110 · 2021: 121 · 2020: 149 · 2019: 135 · 2018: 91
- FWCI
- 96.74
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- Monash University Research Portal (Monash University) (publishedVersion, other-oa)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (publishedVersion)
- St George's Online Research Archive (St George's University of London) (acceptedVersion)
- UNSWorks (University of New South Wales, Sydney, Australia) (submittedVersion, cc-by-nc-nd)
- UWA Profiles and Research Repository (UWA) (submittedVersion)
- Adelaide Research & Scholarship (AR&S) (University of Adelaide) (submittedVersion)
- Research Repository (Kingston University London) (submittedVersion)
- ePrints Soton (University of Southampton) (submittedVersion)
- Funders
- National Health and Medical Research Council (1004108, 1124926)
- Health Research Council of New Zealand (12/206)
- National Institute of Health Research, United Kingdom
- Topics
- Health Sciences › Medicine › Critical Care and Intensive Care Medicine › Sepsis Diagnosis and Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hyperglycemia and glycemic control in critically ill and hospitalized patients
- Keywords
- septic shock, cortisol, mortality, mechanical ventilation, shock resolution, blood transfusion, intensive care unit, sepsis treatment, subgroup analysis, mechanical ventilation duration, vasopressor requirement, glycemic control
- MeSH terms
- Aged, Anti-Inflammatory Agents, Double-Blind Method, Female, Humans, Hydrocortisone, Infusions, Intravenous, Male, Middle Aged, Recurrence, Respiration, Artificial, Shock, Septic, Survival Rate, Fungemia, Bacteremia, Treatment Outcome, Chemotherapy, Adjuvant, Renal Replacement Therapy, APACHE
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.